We are live on
!
Find out more
IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
1-Year Est. Return
17.25%
This Fund
S&P 500
This Quarter
Est. Return
-7.62%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$297M
AUM Growth
-$31.7M
(-9.6%)
Cap. Flow
-$5.36M
Cap. Flow
% of AUM
-1.8%
Top 10 Holdings %
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5
Top Buys
| 1 |
uniQure
QURE
|
+$11M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$8.45M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$8.21M |
| 4 |
Biogen
BIIB
|
+$7.81M |
| 5 |
Gilead Sciences
GILD
|
+$6.85M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$14.3M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$11.8M |
| 3 |
Amgen
AMGN
|
+$9.48M |
| 4 |
Harmony Biosciences
HRMY
|
+$8.89M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$8.55M |
Sector Composition
| 1 | Healthcare | 99.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$193B
| $21.3M | 7.17% |
79,246
-38,000
| -32% | -$9.48M |
|
2
Incyte
INCY
$23B
| $20.7M | 6.97% |
358,454
| – | – |
|
|
3
Gilead Sciences
GILD
$164B
| $17.5M | 5.9% |
233,584
+89,000
| +62% | +$6.85M |
|
|
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $16.5M | 5.57% |
317,856
+141,000
| +80% | +$8.21M |
|
|
5
BioMarin Pharmaceuticals
BMRN
$11.4B
| $13.6M | 4.58% |
153,656
+95,000
| +162% | +$8.45M |
|
6
Supernus Pharmaceuticals
SUPN
$2.77B
| $11.8M | 3.96% |
426,500
-97,000
| -19% | -$2.95M |
|
7
Vera Therapeutics
VERA
$3.05B
| $10.4M | 3.5% |
758,355
-216,872
| -22% | -$3.72M |
|
|
8
Biogen
BIIB
$29.1B
| $10.3M | 3.48% |
40,200
+29,200
| +265% | +$7.81M |
|
|
9
Harmony Biosciences
HRMY
$2.02B
| $10.3M | 3.47% |
314,500
-256,000
| -45% | -$8.89M |
|
|
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.4M | 3.17% |
216,000
-44,000
| -17% | -$1.57M |
|
11
Ultragenyx Pharmaceutical
RARE
$3.12B
| $8.91M | 3% |
250,052
+170,000
| +212% | +$6.74M |
|
|
12
uniQure
QURE
$2.82B
| $8.33M | 2.81% |
1,241,500
+1,226,000
| +7,910% | +$11M |
|
13
Aurinia Pharmaceuticals
AUPH
$2.07B
| $8.07M | 2.72% |
1,040,530
+467,000
| +81% | +$4.57M |
|
14
United Therapeutics
UTHR
$22.6B
| $7.66M | 2.58% |
33,959
-18,800
| -36% | -$4.33M |
|
15
Vertex Pharmaceuticals
VRTX
$121B
| $7.3M | 2.46% |
21,000
| – | – |
|
|
16
Regeneron Pharmaceuticals
REGN
$69.7B
| $7.28M | 2.45% |
8,847
-18,153
| -67% | -$14.3M |
|
17
Illumina
ILMN
$28.3B
| $6.93M | 2.34% |
51,914
| – | – |
|
|
18
Alnylam Pharmaceuticals
ALNY
$37.3B
| $6.52M | 2.2% |
36,800
-44,800
| -55% | -$8.55M |
|
19
Amylyx Pharmaceuticals
AMLX
$1.98B
| $5.4M | 1.82% |
295,000
+270,000
| +1,080% | +$5.71M |
|
20
Krystal Biotech
KRYS
$10.3B
| $5.34M | 1.8% |
46,092
+147
| +0.3% | +$17.9K |
|
|
KRTX
21
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $5.16M | 1.74% |
30,500
+4,800
| +19% | +$903K |
|
22
Axsome Therapeutics
AXSM
$12.2B
| $4.07M | 1.37% |
58,300
| – | – |
|
23
Erasca
ERAS
$6.61B
| $3.79M | 1.28% |
1,926,000
+500,000
| +35% | +$1.28M |
|
24
Acadia Pharmaceuticals
ACAD
$4.44B
| $3.74M | 1.26% |
179,702
+28,702
| +19% | +$780K |
|
|
RVNC
25
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.31M | 1.11% |
288,726
| – | – |
|
Similar funds
DCMIC
DT
3LCM
TFA
SFG
AEPLI
BC
KBC